Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Author(s):
Marina, N.M.; Smeland, S.; Bielack, S.S.; Bernstein, M.; Jovic, G.; Krailo, M.D.; Hook, J.M.; Arndt, C.; Berg, H. van den; Brennan, B.; Brichard, B.; Brown, K.L.B.; Butterfass-Bahloul, T.; Calaminus, G.; Daldrup-Link, H.E.; Eriksson, M.; Gebhardt, M.C.; Gelderblom, H.; Gerss, J.; Goldsby, R.; Goorin, A.; Gorlick, R.; Grier, H.E.; Hale, J.P.; Hall, K.S.; Hardes, J.; Hawkins, D.S.; Helmke, K.; Hogendoorn, P.C.W. (0000-0002-1513-8104); Isakoff, M.S.; Janeway, K.A.; Jurgens, H.; Kager, L.; Kuhne, T.; Lau, C.C.; Leavey, P.J.; Lessnick, S.L.; Mascarenhas, L.; Meyers, P.A.; Mottl, H.; Nathrath, M.; Papai, Z.; Randall, R.L.; Reichardt, P.; Renard, M.; Safwat, A.A.; Schwartz, C.L.; Stevens, M.C.G.; Strauss, S.J.; Teot, L.; Werner, M.; Sydes, M.R.; Whelan, J.S.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-10-31
Language
English
Is part of
The Lancet Oncology (2016), Vol. 17, no. 10, p. 1396-1408
hdl
1887/112891
doi
10.1016/S1470-2045(16)30214-5